Process for the synthesis of E1 activating enzyme inhibitors

US10745404B2 · kind B2 · utility

Assignee

• Millennium Pharmaceuticals, Inc. · US

Inventors

• Ian Armitage · Stoneham, US
• Eric L. Elliott · Watertown, US
• Marianne Langston · North Andover, US
• Steven P. Langston · North Andover, US
• Quentin J. McCubbin · Belmont, US
• Hiro Mizutani · Cambridge, US
• Matthew Stirling · Boston, US
• Lei Zhu · Hefei, CN

Key dates

• Filing date: Sep 22, 2017
• Grant date: Aug 18, 2020
• Expiry date: Sep 22, 2037

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02P20/55
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides processes and synthetic intermediate (Ia) for the synthesis of 4-substituted ((1S, 2S, 4R)-2-hydroxy-4-{7H-pyrrolo[2,3-d]pyrimidin-7-yl}cyclopentyl)methyl sulfamates. These sulfamate compounds are E1 activating enzyme inhibitors, and are useful for the treatment of disorders of cell proliferation, particularly cancer, and other disorders associated with E1 activity.